Sudarshan Pharma [SUDARSHAN] vs Deepak Nitrite [DEEPAKNTR] Detailed Stock Comparison
Sudarshan Pharma
BSE
Loading...
Deepak Nitrite
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sudarshan Pharma wins in 6 metrics, Deepak Nitrite wins in 12 metrics, with 0 ties. Deepak Nitrite appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sudarshan Pharma | Deepak Nitrite | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 29.86 | 41.67 | Sudarshan Pharma |
| Price-to-Book Ratio | 4.76 | 4.69 | Deepak Nitrite |
| Debt-to-Equity Ratio | 129.85 | 23.36 | Deepak Nitrite |
| PEG Ratio | N/A | -0.93 | N/A |
| EV/EBITDA | 16.49 | 26.23 | Sudarshan Pharma |
| Profit Margin (TTM) | 3.83% | 7.58% | Deepak Nitrite |
| Operating Margin (TTM) | 6.99% | 7.32% | Deepak Nitrite |
| EBITDA Margin (TTM) | 6.99% | 7.32% | Deepak Nitrite |
| Return on Equity | 12.13% | 11.85% | Sudarshan Pharma |
| Return on Assets (TTM) | 3.96% | 9.03% | Deepak Nitrite |
| Free Cash Flow (TTM) | $304.76M | $-5.12B | Sudarshan Pharma |
| Dividend Yield | N/A | 0.41% | N/A |
| 1-Year Return | -93.27% | -34.84% | Deepak Nitrite |
| Price-to-Sales Ratio (TTM) | 1.13 | 3.16 | Sudarshan Pharma |
| Enterprise Value | $7.94B | $256.48B | Deepak Nitrite |
| EV/Revenue Ratio | 1.44 | 3.20 | Sudarshan Pharma |
| Gross Profit Margin (TTM) | 11.05% | 21.99% | Deepak Nitrite |
| Revenue per Share (TTM) | $23 | $587 | Deepak Nitrite |
| Earnings per Share (Diluted) | $0.87 | $44.44 | Deepak Nitrite |
| Beta (Stock Volatility) | 0.68 | 0.14 | Deepak Nitrite |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sudarshan Pharma vs Deepak Nitrite Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sudarshan Pharma | 4.99% | 4.88% | -15.13% | -6.93% | -11.29% | -38.71% |
| Deepak Nitrite | -2.27% | 0.56% | 5.64% | -6.88% | 1.10% | -26.19% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sudarshan Pharma | -93.27% | -51.13% | -51.13% | -51.13% | -51.13% | -51.13% |
| Deepak Nitrite | -34.84% | -17.13% | 156.62% | 2,712.81% | 9,563.52% | 10,252.61% |
News Based Sentiment: Sudarshan Pharma vs Deepak Nitrite
Sudarshan Pharma
News based Sentiment: NEGATIVE
Sudarshan Pharma faces significant headwinds, including a substantial year-to-date stock decline, negative analyst ratings predicting a 48% decline, and concerning valuation metrics. While the upcoming IPO presents a potential opportunity, the overall narrative is one of caution and risk, making this a pivotal moment for the company.
Deepak Nitrite
News based Sentiment: MIXED
October presented a mixed bag for Deepak Nitrite, with declining quarterly results countered by a significant investment in R&D and continued regulatory compliance. While the company faces short-term headwinds, its commitment to innovation and strong market position suggest potential for future growth, creating a balanced investment narrative.
Performance & Financial Health Analysis: Sudarshan Pharma vs Deepak Nitrite
| Metric | SUDARSHAN | DEEPAKNTR |
|---|---|---|
| Market Information | ||
| Market Cap | ₹6.56B | ₹253.61B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 53,200 | 221,309 |
| 90 Day Avg. Volume | 77,333 | 235,342 |
| Last Close | ₹28.63 | ₹1,802.00 |
| 52 Week Range | ₹24.69 - ₹53.50 | ₹1,733.90 - ₹3,011.15 |
| % from 52W High | -46.49% | -40.16% |
| All-Time High | ₹452.70 (Sep 30, 2024) | ₹3,169.00 (Jul 29, 2024) |
| % from All-Time High | -93.68% | -43.14% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.46% | -0.13% |
| Quarterly Earnings Growth | N/A | -0.45% |
| Financial Health | ||
| Profit Margin (TTM) | 0.04% | 0.08% |
| Operating Margin (TTM) | 0.07% | 0.07% |
| Return on Equity (TTM) | 0.12% | 0.12% |
| Debt to Equity (MRQ) | 129.85 | 23.36 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹5.46 | ₹395.08 |
| Cash per Share (MRQ) | ₹0.09 | ₹66.90 |
| Operating Cash Flow (TTM) | ₹8.46M | ₹7.00B |
| Levered Free Cash Flow (TTM) | ₹159.55M | ₹6.97B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.41% |
| Last 12-Month Dividend | N/A | ₹7.50 |
Valuation & Enterprise Metrics Analysis: Sudarshan Pharma vs Deepak Nitrite
| Metric | SUDARSHAN | DEEPAKNTR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 29.86 | 41.67 |
| Forward P/E | N/A | 27.92 |
| PEG Ratio | N/A | -0.93 |
| Price to Sales (TTM) | 1.13 | 3.16 |
| Price to Book (MRQ) | 4.76 | 4.69 |
| Market Capitalization | ||
| Market Capitalization | ₹6.56B | ₹253.61B |
| Enterprise Value | ₹7.94B | ₹256.48B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.44 | 3.20 |
| Enterprise to EBITDA | 16.49 | 26.23 |
| Risk & Other Metrics | ||
| Beta | 0.68 | 0.14 |
| Book Value per Share (MRQ) | ₹5.46 | ₹395.08 |
Financial Statements Comparison: Sudarshan Pharma vs Deepak Nitrite
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SUDARSHAN | DEEPAKNTR |
|---|---|---|
| Revenue/Sales | ₹1.45B | ₹18.90B |
| Cost of Goods Sold | ₹1.29B | ₹14.74B |
| Gross Profit | ₹160.46M | ₹4.16B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹101.60M | ₹1.38B |
| EBITDA | ₹122.50M | ₹2.14B |
| Pre-Tax Income | ₹54.09M | ₹1.55B |
| Income Tax | ₹14.51M | ₹424.90M |
| Net Income (Profit) | ₹39.59M | ₹1.12B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SUDARSHAN | DEEPAKNTR |
|---|---|---|
| Cash & Equivalents | ₹5.51M | ₹1.79B |
| Total Current Assets | ₹3.35B | ₹32.97B |
| Total Current Liabilities | ₹2.60B | ₹9.23B |
| Long-Term Debt | ₹104.60M | ₹11.14B |
| Total Shareholders Equity | ₹1.31B | ₹54.25B |
| Retained Earnings | N/A | ₹48.27B |
| Property, Plant & Equipment | ₹200.50M | ₹24.00B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SUDARSHAN | DEEPAKNTR |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SUDARSHAN | DEEPAKNTR |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 53,200 | 221,309 |
| Average Daily Volume (90 Day) | 77,333 | 235,342 |
| Shares Outstanding | 240.66M | 136.39M |
| Float Shares | 71.19M | 67.98M |
| % Held by Insiders | 0.76% | 0.50% |
| % Held by Institutions | 0.00% | 0.26% |
Dividend Analysis & Yield Comparison: Sudarshan Pharma vs Deepak Nitrite
| Metric | SUDARSHAN | DEEPAKNTR |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹7.50 |
| Last 12-Month Dividend Yield | N/A | 0.41% |
| 3-Year Avg Annual Dividend | N/A | ₹7.50 |
| 3-Year Avg Dividend Yield | N/A | 0.34% |
| 3-Year Total Dividends | N/A | ₹22.50 |
| Ex-Dividend Date | N/A | Aug 04, 2025 |